structure of glp 1 GLP-1 receptor biology: structure, signaling, and distribution GLP-1R Agonist DMB | Glucagon

Common side effects Most people experience mild to moderate side effects, especially when starting the medication or adjusting to a higher dose

*These statements have not been evaluated by the FDA

These were more frequent and dose dependent with monlunabant compared with placebo

The actual monthly cost may be higher depending on the specific medication, dosage, and quantity prescribed

Pomalyst (pomalidomide) Disease area(s): Oncology/hematology Manufacturer(s): Bristol Myers Squibb 2024 Sales (USD): $3.55 billion Why it sold so well: Bristol Myers Squibbs blood cancer drug Pomalyst netted global sales of $3.55 billion, an increase of 3% from the previous year and accounted for approximately 7.3% of the companys total revenue of $48.3 billion in 2024